Journals / Anadolu Kliniği Tıp Bilimleri Dergisi / 2020 / Sayı: Special Issue on COVID 19

Mast cell stabilizers as a supportive therapy can contribute to alleviate fatal inflammatory responses and severity of pulmonary complications in COVID-19 infection

Destekleyici bir tedavi olarak mast hücre stabilizatörleri COVID-19 enfeksiyonunda ölümcül inflamatuar yanıtları ve pulmoner komplikasyonların şiddetini hafifletmeye katkıda bulunabilir

Pages
111–118
Publication Date
2020-03-20
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

SARS-CoV-2-induced abnormal production and release of these mediators from MCs can further exacerbate inflammation in respiratory system, consequently pulmonary complications.Therefore administration of MC stabilizers as a supportive therapy may be useful to alleviate inflammatory responses and pulmonary complications in order to reduce deaths from SARS-CoV-2 infection.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:SARS-CoV-2(COVID-19) leads to severe acute respiratory syndrome by settling the pulmonary system.
📊
Key Findings & Data:Severe acute respiratory syndrome with proinflammatory cytokine release and pneumonia during COVID-19 infection can result in the death, in particular in debilitated individuals or those suffering from related chronic disorders.
💡
Conclusion & Impact:SARS-CoV-2-induced abnormal production and release of these mediators from MCs can further exacerbate inflammation in respiratory system, consequently pulmonary complications.Therefore administration of MC stabilizers as a supportive therapy may be useful to alleviate inflammatory responses and pulmonary complications in order to reduce deaths from SARS-CoV-2 infection.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:SARS-CoV-2 · COVID-19 · mast hücreleri

Abstract

SARS-CoV-2(COVID-19) leads to severe acute respiratory syndrome by settling the pulmonary system. Mast cells (MCs) are multifunctional immune cells that are extensively distributed throughout the body and mostly present in pulmonary system. MCs play a vital role in acquired and innate immunity, and to maintain immune homeostasis of the body through a wide range of mediators in their cytoplasmic granules. Severe acute respiratory syndrome with proinflammatory cytokine release and pneumonia during COVID-19 infection can result in the death, in particular in debilitated individuals or those suffering from related chronic disorders. In this review, we attempt to discuss potential relationship between COVID-19 symptoms and mast cells as well as potential use of mast cell stabilizers as a supportive therapeutic option in COVID-19 infection. MCs are main source of pro-inflammatory cytokines such as IL-1, IL-6 and TNF-α as well as bronchoconstrictor mediators such as histamine, prostaglandin-D2 and leukotriene-C4 that can lead to fatal inflammatory responses and pulmonary complications during COVID-19 infection. SARS-CoV-2 may activate MCs through toll-like receptors or by inducing the cross-linking of the IgE-FcεRI, thus leading to release of those mediators. SARS-CoV-2-induced abnormal production and release of these mediators from MCs can further exacerbate inflammation in respiratory system, consequently pulmonary complications.Therefore administration of MC stabilizers as a supportive therapy may be useful to alleviate inflammatory responses and pulmonary complications in order to reduce deaths from SARS-CoV-2 infection.

Özet

SARS-CoV-2 (COVID-19) pulmoner sisteme yerleşerek ciddi akut solunum yetmezliği sendromuna yol açmaktadır. Mast hücreleri vücutta yaygın dağılım gösteren ve pulmoner sistemde bol miktarda bulunan çok fonksiyonlu bağışıklık hücreleridir. Mast hücreleri doğal ve kazanılmış bağışıklıkta ve vücudun bağışıklık homeostazının sürdürülmesinde sitoplazmik granüllerindeki çeşitli mediyatörler aracılığıyla hayati bir rol oynamaktadır. COVID-19 enfeksiyonu sırasında pro-inflamatuar sitokin salınımı ve pnömoni ile karakterize ağır akut solunum yetmezliği özellikle zayıf veya ilişkili kronik hastalıklardan muzdarip bireylerde ölümle sonuçlanabilmektedir. Bu derlemede COVID-19 semptomları ve mast hücreleri arasındaki potansiyel ilişkiyi ve destekleyici bir terapötik seçenek olarak mast hücre stabilizatörlerinin COVID-19 enfeksiyonunda potansiyel kullanımını tartışmaya çalıştık. Mast hücreleri, COVID-19 enfeksiyonu sırasında ölümcül inflamatuar yanıtları ve pulmoner komplikasyonları tetikleyebilen IL-1, IL-6 ve TNF-α gibi pro-inflamatuar sitokinlerin ve histamin, prostaglandin-D2 ve lökotrien-C4 gibi bronkokonstriktör mediyatörlerin ana kaynağıdır. SARS-CoV-2, mast hücrelerini toll-like reseptörleri aracılığıyla veya IgE-FcεRI’nın çapraz bağlanmasını tetikleyerek aktive edebilir ve böylece mast hücrelerinden bu mediyatörlerin salınımına yol açar. Mast hücrelerinden bu mediyatörlerin SARS-CoV-2 ile tetiklenmiş anormal üretimi ve salınımı solunum sisteminde inflamasyonu ve sonuçta pulmoner komplikasyonları daha fazla kötüleştirebilir. Böylece destekleyici bir tedavi olarak mast hücre stabilizatörlerinin kullanılması SARS-CoV-2 enfeksiyonundan ölümleri azaltmak amacıyla inflamatuar yanıtları ve pulmoner komplikasyonları hafifletmek/iyileştirmek için faydalı olabilir.

🔖

Cite This Article

KILINÇ, E., BARANOĞLU, Y. (2020). Mast cell stabilizers as a supportive therapy can contribute to alleviate fatal inflammatory responses and severity of pulmonary complications in COVID-19 infection. Anadolu Kliniği Tıp Bilimleri Dergisi, Sayı: Special Issue on COVID 19, 111–118. https://ajindex.com/articles/459330

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Ankaralı H, Ankaralı S, Erarslan N. COVID-19, SARS-CoV2, Infection: current epidemiological analysis and modeling of disease. Anatolian Clinic Journal of Medical Sciences, 2020; 25(Supplement 1): 1-22. 2.
  2. Zhu N, Zhang D, Wang W, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med 2020;382(8):727–733. doi:10.1056/NEJMoa2001017 4. Kumar D, Malviya R, Kumar Sharma P. Corona Virus: A review of COVID-19. EJMO 2020; 4(1): 8-25
  3. Shanmugaraj B, Siriwattananon K, Wangkanont K, Phoolcharoen W. Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19). Asian Pac J Allergy Immunol 2020;38(1):10–18
  4. Guo YR, Cao QD, Hong ZS, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status. Mil Med Res 2020;7(1):11
  5. Chan JF, Yuan S, Kok KH, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020;395(10223):514–523. doi:10.1016/S0140-6736(20)30154-9 8. Lu H, Stratton CW, Tang YW. Outbreak of pneumonia of unknown etiology in Wuhan, China: the mystery and the miracle. J Med Virol 2020;92(4):401–402
  6. Koyuncu Irmak D, Kilinc E, Tore F. Shared fate of meningeal mast cells and sensory neurons in migraine. Front Cell Neurosci 2019;13:136
  7. Theoharides TC, Cochrane DE. Critical role of mast cells in inflammatory diseases and the effect of acute stress. J Neuroimmunol 2004;146(1-2):1-12
  8. Kilinc E, Dagistan Y, Kotan B, Cetinkaya A. Effects of Nigella sativa seeds and certain species of fungi extracts on number and activation of dural mast cells in rats. Physiol Int 2017;104(1):15-24. doi: 10.1556/2060.104.2017.1.8
  9. Tete S, Tripodi D, Rosati M, Conti F, Maccauro G, Saggini A, Salini V, Cianchetti E, Caraffa A, Antinolfi P, Toniato E, Castellani ML, Pandolfi F, Frydas S, Conti P, Theoharides TC. Role of mast cells in innate and adaptive immunity. J Biol Regul Homeost Agents. 2012;26(2):193-201
  10. Kilinc E, Balci CN. An investigation of lung mast cell behavior in a rat model of migraine: Implications for migraine headache. Anatol Clin. 2018; 23(3): 151-156. DOI: 10.21673/anadoluklin.429905
  11. Kilinc E, Guerrero-Toro C, Zakharov A, Vitale C, Gubert-Olive M, Koroleva K, T